

## RECORDATI: TERMINATION BY MUTUAL AGREEMENT OF THE EMPLOYMENT RELATIONSHIP WITH ALBERTO RECORDATI

Milan, 1 February 2019 – RECORDATI S.p.A. informs that the Board, in its meeting of today, after taking into account the favourable opinion of the Remuneration Committee, convened on the same date, approved the execution of the termination by mutual agreement of the employment relationship with Alberto Recordati. As previously announced, on 6 December 2018, upon completion of the acquisition of the entire share capital of Fime S.p.A. by Rossini Investimenti S.p.A., Alberto Recordati resigned as director and Chairman of the Board of Directors of Recordati S.p.A..

Said agreement provides that, following the mutual agreement on the termination of the long-term employment relationship, effective today, Alberto Recordati will maintain only the right to exercise the stock options already granted under Stock Option Plan 2014-2018, as an exception to the Plan, but only in respect of the tranches which will vest on May 12, 2019 (if the conditions set forth by the Plan are fulfilled): 27,000 options at the strike price of € 21.93 and 45,000 options at the strike price of € 12.29. Said exception, subject to the approval of the Board of Directors, is provided for in the relative Stock Option plan, which is one of the component of the Remuneration Policy of the Company.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

### Media Relations

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832